ABOUT US
Innovative Biochips is a spin-off company from Houston Texas Medical Center (TMC), a rich environment that places unique assets and a wealth of resources at the disposal of all investigators and researchers in life science field.
Innovative Biochips is committed to develop advanced microfluidic technologies that resolve traditional biotech challenges by achieving cutting-edge sensitivity and high-throughput. The company’s scientists and engineers have extensive and successful experience in developing novel microfluidic technologies for various biological and biomedical applications.
Innovative Biochips has currently 18 international distributors in Europe and Asia, and has engaged Fisher Scientific to sell its products in USA. Moreover, Innovative Biochips has established business collaboration with Thermo Fisher Scientific, Millipore Sigma, BioTek, and Harvard Bioscience that allows key benefits to drive product development.
Grants And Awards
Fierce Innovation Awards: Life Sciences Edition Announce Finalists, Innovative Biochips Recognized
Innovative Biochips has been selected as a finalist in this year’s Fierce Innovation Awards: Life Sciences Edition, an awards program from the publisher of FierceBiotech and FiercePharma. Innovative Biochips was recognized as a finalist in the category of Biotech Innovation.
Innovative Biochips, LLC Awarded Phase II Grant Support from the National Institutes of Health
Innovative Biochips, LLC Awarded Phase II Grant Support from the National Institutes of Health
Innovative Biochips, LLC has been awarded a National Institutes of Health (NIH) Small Business Technology Transfer (STTR) Phase II grant.
This Phase II grant ($1,500,000) supports to continue the research and development efforts of Innovative Biochips for developing an automated dissection system initiated in Phase I grant ($225,000).
The Phase II funding is based on the results achieved in Phase I and the scientific and technical merit and commercial potential of the Phase II project proposed. Only Phase I awardees are eligible for a Phase II award.
This Policy implements Financial Conflicts of Interest (FCOI) disclosure requirements found in 42 CFR Part 50 and 45 CFR Part 94 which are applicable to Research funded by the U.S. Public Health Service (PHS).
As a condition for receiving PHS funding, these regulations require Innovative Biochips LLC to maintain an appropriate written policy on financial conflict of interest disclosure, and make such policy available via a publicly accessible Web site. The Innovative Biochips’ FCOI Policy and FCOI Disclosure Form can be found below.
• Financial Conflict of Interest Policy
• Financial Conflict of Interest Disclosure Form
PUBLICATIONS
via membrane deformation
aging using a microfluidic system
Media Coverage
